R&D News | pharmaphorum

News

Trial could unlock asthma use for GSK’s Trelegy

GlaxoSmithKline CEO Emma Walmsley has been predicting big things for respiratory triple therapy Trelegy in the next couple of years and has new data that could open up a new market.

News

abstract shapes, bone structure, 3d render, bone

UK biotech Mereo gears up for key brittle bone drug data

UK biotech Mereo BioPharma is hoping the coming months will transform its fortunes as it prepares for potentially pivotal data for a brittle bone disease drug.

News

Nimble Therapeutics spins out of Roche to focus on peptide R...

US biotech Nimble Therapeutics has announced it is operating as a standalone business after spinning out from Roche, focusing on drug R&D based around peptides.

News

Lynparza on cusp of approval for advanced ovarian cancer

Breast cancer drug Lynparza (olaparib) is poised for EU approval for the first-line treatment of a certain type of metastatic ovarian cancer.

News

Blow for Gilead as another NASH trial fails

Gilead's attempts to find a treatment for nonalcoholic steatohepatitis (NASH) have been dealt another blow after another trial failure for one of its prime candidates to treat the disease.<

News

UK government hopes CRO cash will boost life sciences

Research and development in the UK will have a major boost thanks to the Medicines Discovery Catapult today launching 22 partnerships with UK-based contract research organisations (CRO

Trial could unlock asthma use for GSK’s Trelegy

UK biotech Mereo gears up for key brittle bone drug data

Nimble Therapeutics spins out of Roche to focus on peptide R...

Lynparza on cusp of approval for advanced ovarian cancer

Blow for Gilead as another NASH trial fails

UK government hopes CRO cash will boost life sciences

Merck's rare tumour drug Pimjetmi claims FDA approval

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks